BDR Pharma receives DGCI nod for its generic drug BIAPENEM, Health News, ET HealthWorld

Mumbai: Pharmaceutical company BDR Pharma launched generic drug BIAPENEM which can be used to treat intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections. BIAPENEM, which will be marketed under the brand name BIAPEN, will be an addition to BDP Pharma’s critical care segment.

BDR Pharma became the first to identify, develop and conduct clinical studies of the drug in conjunction with some of the leading players in the critical care segment who co-sponsored these studies. First approval granted by DCGI (Drug Controller General of India) also went to BDR pharma.
Speaking about the launch of an affordable drug to treat all kinds of infections under the company’s name, Raheel Shah, Director – Business Development, BDR Pharmaceuticals, said, “Further encasing our high standards, the launch of BIAPEN is a welcome addition to the existing range of antibiotics. This drug will cover a broad spectrum of almost every infection and will be a great boon to the medical fraternity and patients. Firmly following the path of accessible and affordable care, we have categorically decided to market this wonder product and we will make arrangements to supply the product to the co-sponsors who will also market it under their brand name.

View More BDR Pharma receives DGCI nod for its generic drug BIAPENEM, Health News, ET HealthWorld

Active COVID-19 cases lowest in 187 days, Health News, ET HealthWorld

India added 31,923 new coronavirus infections taking the total tally of COVID-19 cases to 3,35,63,421, while the active cases declined to 3,01,640, the lowest in 187 days, according to the Union Health Ministry data updated on Thursday.

The death toll climbed to 4,46,050 with 282 fresh fatalities, according to the data updated at 8 am.

The active cases comprise 0.90 per cent of the total infections, the lowest since March 2020, while the national COVID-19 recovery rate was recorded at 97.77 per cent, the highest since March 2020, the ministry said.

As many as 15,27,443 tests were conducted on Wednesday taking the total cumulative tests conducted so far for detection of COVID-19 in the country to 55,83,67,013.

The daily positivity rate was recorded at 2.09 per cent. It has been less than three per cent for last 24 days. The weekly positivity rate was recorded at 2.11 per cent. It has been below three per cent for the last 90 days, according to the ministry.

The number of people who have recuperated from the disease surged to 3,28,15,731, while the case fatality rate was recorded at 1.33 per cent.

The cumulative doses administered in the country so far under the

View More Active COVID-19 cases lowest in 187 days, Health News, ET HealthWorld

Britain begins trial of multivariant COVID-19 vaccine booster, Health News, ET HealthWorld

A phase one trial of a multivariant COVID-19 vaccine booster drug has got underway among participants aged over 60 in the UK.

The trial, involving GRT-R910, has been launched by US pharmaceutical company Gritstone in collaboration with the University of Manchester and Manchester University NHS Foundation Trust. It will explore the potential of the drug to boost the immune response of first-generation COVID-19 vaccines to a wide array of variants of Sars-Cov-2, which cause COVID-19.

“We think GRT-R910 as a booster vaccination will elicit strong, durable, and broad immune responses, which are likely to be critical in maintaining protection of this vulnerable elderly population who are particularly at risk of hospitalisation and death,” said Professor Andrew Ustianowski, Chief Investigator for the study from the North Manchester General Hospital.

“We now know the immune response to first generation vaccines can wane, particularly in older people. Coupled with the prevalence of emerging variants, there is a clear need for continued vigilance to keep COVID-19 at bay,” he said.

Part of Gritstone’s CORAL programme, GRT-R910 is described as a self-amplifying mRNA second generation SARS-CoV-2 vaccine – or SAM for short, which delivers antigens from both the spike and non-spike proteins.

“Our SAM COVID-19

View More Britain begins trial of multivariant COVID-19 vaccine booster, Health News, ET HealthWorld